PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy

作     者：Long Jia Qi Zhang Rongxin Zhang 

作者机构：Laboratory of Immunology and InflammationDepartment of Immunology and Research Center of Basic Medical SciencesKey Laboratory of Immune Microenvironments and Diseases of Educational MinistryTianjin Medical University Institute of Integrative Medicines for Acute Abdominal DiseasesTianjin Nankai Hospital Guangdong Province Key Laboratory for Biotechnology Drug CandidatesSchool of Life Sciences and BiopharmaceuticsGuangdong Pharmaceutical University 

出 版 物：《Cancer Biology & Medicine》 (癌症生物学与医学（英文版）)

年 卷 期：2018年第15卷第2期

页      面：116-123页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：3Guangdong Province Key Laboratory for Biotechnology Drug Candidates Basic Medical Sciences Integrative Medicines for Acute Abdominal Diseases Tianjin Nankai Hospital Tianjin Medical University 

主　　题：PD-1 PD-L1 cancer immunotherapy 

摘      要：Cancer immunotherapy has greatly advanced in recent years,and PD-1/PD-L1 blocking therapy has become a major pillar of *** clinical trials of PD-1/PD-L1 blocking therapies in cancer treatments have benefited many patients,which promoted the Food and Drug Administration(FDA)approval of PD-1/PD-L1 blocking *** this review,we provide a detailed introduction of five PD-1/PD-L1 blocking drugs,with indications and studies,as a valuable reference for doctors and medical ***,the characteristics of PD-1/PD-L1 blocking therapies,including their universality and sustainability,are discussed in this ***,we also discuss and predict the possibility of PD-L1 as an indication marker of PD-1/PD-L1 blocking therapy for pan-cancer treatment,and the current status of combination therapies.